Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib + ezetimibe coronary plaque CCTA trial in ASCVD
NL-OMON59274Phase 3Recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Nov 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Obicetrapib + ezetimibe fixed-dose combination with Placebo (2 arms). Primary endpoint: Percent change in total non-calcified plaque volume. Started Nov 2024; status: recruiting.
02
Drugs
obicetrapibezetimibe
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on NL-OMON59274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59274.